XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 32.13

-0.5%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: E.J. Neitz Jr who wrote (6406)	6/4/1998 1:05:00 AM
From: aknahow	Read Replies (1) of 17367

Little things mean a lot! Or why I like XOMA. From a series of lectures, and this specific one on antibiotic resistance comes the following statement: Surprisingly, Streptococcus pyogenes (Group A strep) have never fully developed resistance to penicillin and it remains a reasonable choice antibiotic for many types of streptococcal infections. Interestingly, penicillin has never been effective against most Gram-negative pathogens (e.g. Salmonella, Shigella, Bordetella pertussis, Yersinia pestis, Pseudomonas) with the notable exception of Neisseria gonorrhoeae. Gram-negative bacteria are inherently resistant to penicillin because their vulnerable cell wall is protected by an outer membrane that prevents permeation of the penicillin molecule. Certainally makes me believe BPI will have a role in dealing with these bacteria!!! Entire series is at: bact.wisc.edu Recomend Pseudomonas Aeruginosa lecture. XOMA annual report Fig 3a with caption states "It is also the most common multi-drug resistant pathogen in cystic fibrosis patients"

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next